Private Residence, London, UK.
Bordeaux University Hospital, 33000 Bordeaux, France.
Future Oncol. 2021 Feb;17(4):403-409. doi: 10.2217/fon-2020-0652. Epub 2020 Oct 8.
To examine the prognostic value of the platelet-to-lymphocyte ratio (PLR) in the adjuvant renal cell carcinoma setting. Patients received adjuvant sunitinib (50 mg/day; 4 weeks on/2 weeks off) or placebo. The primary end point was disease-free survival (DFS). In 609 patients, DFS was similar for baseline PLR <140 versus ≥140 overall (median: 6.4 vs 5.9 years; hazard ratio: 0.9; 95% CI: 0.7-1.2). A ≥25% decrease in PLR at week 4 overall was associated with longer DFS versus no change (hazard ratio: 0.8; 95% CI: 0.6-1.0). Baseline PLR was not prognostic for DFS with adjuvant sunitinib treatment in patients with renal cell carcinoma. Clinical Trials Registration: NCT00375674 (ClinicalTrials.gov).
探讨血小板与淋巴细胞比值（PLR）在辅助肾细胞癌治疗中的预后价值。患者接受辅助舒尼替尼（50mg/天；4 周用药/2 周停药）或安慰剂治疗。主要终点为无病生存期（DFS）。在 609 例患者中，基线 PLR<140 与≥140 的患者的 DFS 相似（中位：6.4 与 5.9 年；风险比：0.9；95%CI：0.7-1.2）。PLR 在第 4 周总体下降≥25%与无变化相比，DFS 更长（风险比：0.8；95%CI：0.6-1.0）。对于接受辅助舒尼替尼治疗的肾细胞癌患者，基线 PLR 对 DFS 无预后价值。临床试验注册：NCT00375674（ClinicalTrials.gov）。
